Jaswant Singh Basraon, DO
Cardiovascular Disease (Cardiology) · Fresno
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 6
- Since medical school
- 20 years
- Graduated 2006
Offices
6 locations · Community Foundation Medical Group · Fresno Community Hospital and Medical Center
Hospitals listed: Clovis Community Medical Center · Community Regional Medical Center · Saint Agnes Medical Center. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Basraon’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence G11348 · Cancelled
Licence status: Cancelled · since 1965 · State University of New York at Buffalo School of Medicine.
License has been voluntarily canceled, or the license has been expired for at least five years and has not been renewed. No practice is permitted.
Matched on the licence number without its letter prefix; check the name before relying on it.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
State licence records
2 licences
- Texas N6161Physician License · since 2010 · expires 2019-11-30Canc Non-RenewalNo board action on this licenceCheck it with the state
- Texas BP10026266Physician-in-Training Permit · since 2006 · expires 2009-06-30Permit TerminatedNo board action on this licenceCheck it with the state
We check Colorado, Delaware, Florida, Illinois, Maryland, New Jersey, New York, Tennessee, Texas, Virginia, Washington, plus California above. A state that is not in this list has not been checked, which is not the same as clear.
Hospitals they work in
3 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Clovis Community Medical CenterClovis, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Community Medical Centers, which runs 4 hospitalsPatients rate it 3 of 5 · 80% would definitely recommend itOverall rating: 2 of 5 starsWorse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.7 (12.1 to 17.7) · 421 cases, Jan 2024 – Dec 2024Better than the national rate — Clostridium Difficile (C.Diff): 0.692, Oct 2024 – Sep 2025
- Community Regional Medical CenterFresno, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Community Medical Centers, which runs 4 hospitalsPatients rate it 3 of 5 · 70% would definitely recommend itOverall rating: 1 of 5 starsWorse than the national rate — Death rate among surgical inpatients with serious treatable complications: 211.21 (174.88 to 247.54) · 239 cases, Jul 2022 – Jun 2024Better than the national rate — Clostridium Difficile (C.Diff): 0.705, Oct 2024 – Sep 2025
- Saint Agnes Medical CenterFresno, CAAcute Care Hospital · Voluntary non-profit - Church · Has an emergency department · Birthing-friendlyPart of Trinity Health, which runs 105 hospitals in 16 statesPatients rate it 3 of 5 · 76% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.274, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.312, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.141, Oct 2024 – Sep 2025
See every measure and the patient survey for Clovis Community Medical Center
Behind the star rating — Deaths: 1 better, 7 the same, 0 worse of 8 measures. Safety: 0 better, 6 the same, 1 worse of 7 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.7 (12.1 to 17.7) · 421 cases | Worse | Jan 2024 – Dec 2024 |
| Clostridium Difficile (C.Diff)Infections | 0.692 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.97 (0.04 to 1.89) · 1,840 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.16 (0.86 to 1.45) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 217.06 (167.45 to 266.67) · 84 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.4 · 69 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 9.1 · 165 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 13.4 · 161 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 14 · 507 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 17.6 · 798 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 336 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.1 · 3,771 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.19 (0 to 0.39) · 8,649 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.08 to 0.46) · 9,146 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.46 (1.47 to 5.45) · 1,654 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.19 (0.61 to 3.78) · 387 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.18 (0.7 to 3.66) · 1,578 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 13.47 (7.08 to 19.87) · 374 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.99 (1.37 to 8.61) · 379 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.58 (0.13 to 3.04) · 405 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.8 (0.23 to 1.38) · 8,198 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.2 · 90 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.651 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.922 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.449 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.509 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.3 · 210 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 23 · 702 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -1.5 · 152 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 58.4 · 556 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 18 · 769 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.8 · 802 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.5 (4 to 7.4) · 421 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.2 · 91 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 93 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 200 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.8 to 15.6) · 2,398 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.6 to 1.1) · 720 cases | No different | Jan 2024 – Dec 2024 |
What patients said (441 patients answered, 26% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 80% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 69% |
| Doctors "always" listened carefully | 73% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 72% |
| Staff "always" explained new medications | 74% |
| Nurses "always" explained things so they could understand | 71% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 83% |
| "Always" quiet at night | 52% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 48% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
See every measure and the patient survey for Community Regional Medical Center
Behind the star rating — Deaths: 0 better, 7 the same, 1 worse of 8 measures. Safety: 0 better, 7 the same, 0 worse of 7 measures. Readmissions: 0 better, 7 the same, 3 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 211.21 (174.88 to 247.54) · 239 cases | Worse | Jul 2022 – Jun 2024 |
| Clostridium Difficile (C.Diff)Infections | 0.705 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.13 (0.29 to 1.96) · 2,304 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.09 (0.87 to 1.3) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 3.2 · 187 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 116 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.7 · 187 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.6 · 445 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.2 · 399 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 582 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.2 · 3,744 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.31 (0.12 to 0.5) · 11,052 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.45) · 11,566 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.33 (1.64 to 5.01) · 3,139 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.08 (0 to 2.3) · 1,423 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.7 (0.52 to 2.88) · 3,084 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.85 (8.11 to 15.6) · 1,481 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.4 (3.81 to 8.98) · 1,404 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.35 (0.95 to 3.76) · 760 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.64 (0.16 to 1.11) · 10,254 cases | No different | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.817 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 1.031 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.837 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.81 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.853 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.8 · 258 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22 · 689 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 37.4 · 202 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 35.2 · 543 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 39.2 · 434 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19.3 · 552 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.4 (3.6 to 7.9) · 169 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 11.4 (8.3 to 15.4) · 169 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for CABGUnplanned return visits | 12.4 · 189 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21.6 · 248 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 11.9 (9.5 to 14.9) · 2,590 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 310 cases | No different | Jan 2024 – Dec 2024 |
What patients said (421 patients answered, 26% of those asked)
| Cleanliness | 4 |
| Nurse communication | 2 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 1 |
| Recommend hospital | 3 |
| Room was "always" clean | 74% |
| Nurses "always" communicated well | 74% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 55% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 76% |
| Doctors "always" treated them with courtesy and respect | 83% |
| Patients who gave a rating of "9" or "10" (high) | 66% |
| Staff "always" explained new medications | 69% |
| Nurses "always" explained things so they could understand | 70% |
| Nurses "always" listened carefully | 70% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 43% |
| "YES", patients would definitely recommend the hospital | 70% |
| Staff "always" explained possible side effects | 41% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
See every measure and the patient survey for Saint Agnes Medical Center
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 2 better, 6 the same, 0 worse of 8 measures. Readmissions: 0 better, 6 the same, 3 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.274 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.312 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.141 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.18 to 1.94) · 2,342 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.76 to 1.27) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 197.82 (152.64 to 243.01) · 103 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 3.9 · 105 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.3 · 300 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.9 · 295 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.8 · 768 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.8 · 969 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.2 · 304 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.7 · 4,305 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.24 (0.06 to 0.42) · 11,641 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.25 (0.07 to 0.43) · 12,213 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.76 (2.91 to 6.61) · 2,466 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.09 (0 to 2.49) · 864 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.61 (0.26 to 2.96) · 2,362 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.1 (5.39 to 14.81) · 900 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.4 (1.2 to 7.59) · 882 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.84 (0.41 to 3.27) · 541 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.67 (0.14 to 1.19) · 9,626 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.9 · 58 cases | None | Apr 2023 – Mar 2025 |
| MRSA BacteremiaInfections | 0.835 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 1.182 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.004 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.8 · 412 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.6 · 1,002 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 28.8 · 296 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 25.5 · 894 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 17.8 · 981 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.1 · 1,061 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5 · 56 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 13.4 · 150 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.3 · 412 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.3 (9.6 to 15.9) · 1,324 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.1) · 863 cases | No different | Jan 2024 – Dec 2024 |
What patients said (812 patients answered, 32% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 73% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 74% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 85% |
| Yes, staff "did" give patients information about help after discharge | 83% |
| Doctors "always" explained things so they could understand | 70% |
| Doctors "always" listened carefully | 73% |
| Doctors "always" treated them with courtesy and respect | 80% |
| Patients who gave a rating of "9" or "10" (high) | 71% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 68% |
| Nurses "always" listened carefully | 70% |
| Nurses "always" treated them with courtesy and respect | 80% |
| "Always" quiet at night | 50% |
| "YES", patients would definitely recommend the hospital | 76% |
| Staff "always" explained possible side effects | 47% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
Original Medicare doctor bills
$1,141,216
Medicare paid this office $1,141,216 for 1,736 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 253 | $308,780 | $1,216 |
| Return visit (30+ min) | 1,371 | $240,369 | $92 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 253 | $208,359 | $410 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 758 | $115,182 | $150 |
| Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | 149 | $104,968 | $695 |
See all 26 services
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 253 | $308,780 | $1,216 |
| Return visit (30+ min) | 1,371 | $240,369 | $92 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 253 | $208,359 | $410 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 758 | $115,182 | $150 |
| Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | 149 | $104,968 | $695 |
| New patient visit (45+ min) | 319 | $36,209 | $114 |
| Short return visit (20+ min) | 276 | $19,540 | $68 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 57 | $18,974 | $333 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 1,422 | $18,446 | $11 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 308 | $17,909 | $57 |
| Heart rhythm recording, analysis, report, review, and interpretation of continous external ekg over more than 48 hours up to 7 days | 50 | $10,545 | $211 |
| Injection, regadenoson, 0.1 mg | 295 | $7,169 | None |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 41 | $6,001 | $136 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 39 | $5,696 | $93 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 56 | $3,972 | $35 |
| Long return visit (40+ min) | 22 | $3,222 | $146 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 150 | $2,925 | $19 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 55 | $2,709 | $49 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 21 | $1,168 | $56 |
| Ultrasound of heart with probe in esophagus, with report | 12 | $1,073 | $83 |
| New patient visit (30+ min) | 11 | $904 | $82 |
| Injection, aminophyllin, up to 250 mg | 45 | $310 | None |
| Ultrasound of heart, follow-up | 13 | $271 | $19 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 32 | $209 | $6 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 11 | $61 | $6 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 18 | $48 | $2 |
Who their Medicare patients are
1,736 Original Medicare patients in 2024. Average age 75 · Under 65 5% · 85 and older 12% · Women 52% · Also on Medicaid 16% · Health risk score 1.24. At or below the middle of the specialty; the typical cardiology clinician is at 1.71.
Conditions among them: High blood pressure 75% · Coronary heart disease 60% · Diabetes 36% · Chronic kidney disease 30% · Heart failure 29% · Atrial fibrillation 20% · Cancer 18% · Depression 17% · COPD 13% · Stroke 7% · Dementia 6%.
The office billed $4,920,305, Medicare allowed $1,497,498 and paid $1,141,216; for 8,968 services of 46 kinds; $7,496 of it was for drugs given in the office and $1,133,720 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 1,736 | 8,968 | 75 | 1.24 | $4,920,305 | $1,141,216 |
| 2023 | 1,520 | 8,233 | 75 | 1.14 | $4,612,685 | $1,144,901 |
| 2022 | 1,300 | 7,309 | 75 | 1.25 | $3,896,201 | $973,254 |
| 2021 | 1,174 | 7,387 | 74 | 1.34 | $3,899,631 | $1,117,732 |
| 2020 | 1,088 | 6,104 | 75 | 1.57 | $2,569,041 | $954,633 |
| 2019 | 968 | 4,445 | 74 | 1.48 | $972,766 | $417,394 |
| 2018 | 760 | 3,683 | 74 | 1.88 | $815,011 | $420,662 |
| 2017 | 735 | 2,994 | 75 | 2.19 | $656,556 | $306,034 |
| 2016 | 712 | 2,461 | 75 | 1.86 | $538,835 | $239,512 |
| 2015 | 173 | 644 | 75 | 1.76 | $135,514 | $64,275 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 26 services
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 286 | $356,981 | $1,248 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 286 | $238,756 | $417 |
| Return visit (30+ min) | 1,074 | $193,849 | $98 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 709 | $117,426 | $162 |
| Injection, regadenoson, 0.1 mg | 327 | $57,479 | None |
| New patient visit (45+ min) | 334 | $39,241 | $117 |
| Short return visit (20+ min) | 354 | $24,972 | $65 |
| Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | 29 | $21,290 | $734 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 334 | $19,506 | $58 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 50 | $19,015 | $380 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 1,179 | $15,308 | $11 |
| Long return visit (40+ min) | 37 | $6,063 | $144 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 33 | $4,809 | $141 |
| Telephone medical discussion with physician, 21-30 minutes | 32 | $3,645 | $104 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 48 | $3,578 | $37 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 28 | $3,493 | $97 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 60 | $3,290 | $55 |
| Telephone medical discussion with physician, 11-20 minutes | 41 | $2,845 | $66 |
| Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | 117 | $2,216 | $19 |
| New patient visit (30+ min) | 18 | $1,308 | $73 |
| Heart rhythm recording continous external ekg over more than 48 hours up to 7 days | 117 | $1,199 | $10 |
| Ultrasound of heart with probe in esophagus, with report | 12 | $1,018 | $85 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 29 | $600 | $21 |
| Injection, aminophyllin, up to 250 mg | 48 | $359 | None |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 22 | $143 | $6 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 14 | $35 | $2 |
2022: 27 services
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 241 | $303,301 | $1,243 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 241 | $202,739 | $415 |
| Return visit (30+ min) | 683 | $117,059 | $97 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 597 | $100,350 | $165 |
| Injection, regadenoson, 0.1 mg | 266 | $52,611 | None |
| New patient visit (45+ min) | 337 | $43,006 | $128 |
| Short return visit (20+ min) | 517 | $39,006 | $67 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 267 | $15,973 | $59 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 1,028 | $13,629 | $11 |
| Telephone medical discussion with physician, 11-20 minutes | 175 | $13,555 | $67 |
| Long return visit (40+ min) | 71 | $11,691 | $146 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 30 | $11,187 | $373 |
| Telephone medical discussion with physician, 21-30 minutes | 92 | $10,146 | $102 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 57 | $9,488 | $161 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 35 | $5,150 | $83 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 84 | $4,747 | $57 |
| Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | 148 | $3,018 | $20 |
| New patient visit (30+ min) | 29 | $2,455 | $85 |
| New patient visit (60+ min) | 13 | $2,372 | $182 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 29 | $2,225 | $38 |
| Heart rhythm recording continous external ekg over more than 48 hours up to 7 days | 148 | $1,768 | $12 |
| Ultrasound of heart with probe in esophagus, with report | 13 | $1,144 | $88 |
| Telephone medical discussion with physician, 5-10 minutes | 18 | $844 | $47 |
| Injection, aminophyllin, up to 250 mg | 46 | $346 | None |
| Ultrasound of heart, follow-up | 16 | $328 | $20 |
| Ultrasound of heart blood flow, valves and chambers | 12 | $175 | $15 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 22 | $61 | $3 |
2021: 28 services
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 302 | $390,397 | $1,293 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 302 | $256,129 | $424 |
| Return visit (30+ min) | 583 | $109,815 | $100 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 507 | $87,370 | $170 |
| Injection, regadenoson, 0.1 mg | 332 | $63,490 | None |
| New patient visit (45+ min) | 289 | $36,740 | $127 |
| Short return visit (20+ min) | 407 | $31,867 | $72 |
| Telephone medical discussion with physician, 11-20 minutes | 256 | $23,275 | $75 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 336 | $20,135 | $60 |
| Long return visit (40+ min) | 76 | $14,790 | $148 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 35 | $14,350 | $410 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 70 | $12,245 | $163 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 844 | $12,002 | $12 |
| Telephone medical discussion with physician, 21-30 minutes | 68 | $8,548 | $107 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 112 | $6,431 | $57 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 35 | $6,163 | $88 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 52 | $5,903 | $86 |
| Telephone medical discussion with physician, 5-10 minutes | 49 | $2,682 | $47 |
| Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | 112 | $2,336 | $20 |
| Ultrasound of heart with probe in esophagus, with report | 15 | $1,525 | $90 |
| Heart rhythm recording continous external ekg over more than 48 hours up to 7 days | 112 | $1,439 | $13 |
| New patient visit (30+ min) | 14 | $1,051 | $75 |
| Injection, aminophyllin, up to 250 mg | 47 | $314 | None |
| Ultrasound of heart, follow-up | 14 | $314 | $21 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 39 | $286 | $7 |
| Electrocardiogram (ecg) 1 to 3 leads with review by physician | 13 | $129 | $10 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 12 | $77 | $6 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 24 | $76 | $3 |
2020: 24 services
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 278 | $366,219 | $1,313 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 279 | $234,200 | $419 |
| Return visit (30+ min) | 622 | $85,749 | $86 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 439 | $77,902 | $171 |
| Injection, regadenoson, 0.1 mg | 313 | $59,248 | None |
| New patient visit (45+ min) | 187 | $22,575 | $121 |
| Short return visit (20+ min) | 345 | $22,476 | $56 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 315 | $18,940 | $59 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 40 | $14,235 | $356 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 705 | $10,389 | $13 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 54 | $9,208 | $164 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 40 | $7,292 | $91 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 75 | $4,553 | $60 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 33 | $3,560 | $87 |
| New patient visit (30+ min) | 40 | $3,413 | $85 |
| External ekg recording for more than 48 hours up to 21 days | 89 | $2,048 | $23 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 89 | $2,016 | $22 |
| Telephone medical discussion with physician, 11-20 minutes | 17 | $981 | $58 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 112 | $640 | $5 |
| Ultrasound of heart, follow-up | 13 | $281 | $22 |
| Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m servic | 19 | $204 | $11 |
| Injection, aminophyllin, up to 250 mg | 23 | $149 | None |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 11 | $68 | $6 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 17 | $49 | $3 |
2019: 21 services
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 73 | $91,133 | $1,248 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 400 | $68,326 | $165 |
| Short return visit (20+ min) | 584 | $40,721 | $55 |
| Return visit (30+ min) | 312 | $39,377 | $84 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 75 | $30,654 | $409 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 73 | $29,870 | $205 |
| New patient visit (45+ min) | 227 | $27,859 | $123 |
| Injection, regadenoson, 0.1 mg | 144 | $26,074 | None |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 76 | $14,461 | $95 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 766 | $11,703 | $13 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 52 | $8,820 | $163 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 146 | $8,115 | $56 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 33 | $3,582 | $83 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 37 | $2,302 | $61 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 74 | $1,634 | $22 |
| External ekg recording for more than 48 hours up to 21 days | 74 | $1,378 | $18 |
| Ultrasound of heart with probe in esophagus, with report | 11 | $994 | $90 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 11 | $240 | $22 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 16 | $119 | $7 |
| Injection, aminophyllin, up to 250 mg | 11 | $71 | None |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 15 | $42 | $3 |
2018: 23 services
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 78 | $108,435 | $1,390 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 349 | $70,063 | $190 |
| Return visit (30+ min) | 264 | $40,048 | $91 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 77 | $29,191 | $190 |
| New patient visit (45+ min) | 203 | $26,727 | $132 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 56 | $25,758 | $460 |
| Injection, regadenoson, 0.1 mg | 134 | $23,621 | None |
| Short return visit (20+ min) | 332 | $23,518 | $62 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 75 | $13,794 | $182 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 56 | $11,943 | $107 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 138 | $8,742 | $63 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 447 | $7,813 | $14 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 115 | $6,543 | $57 |
| Critical care, first 30-74 minutes | 20 | $6,069 | $202 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 55 | $5,218 | $66 |
| Electrocardiogram (ecg) 2-day continuous with review by health care professional | 67 | $1,715 | $25 |
| Electrocardiogram (ecg) 2-day continuous | 67 | $1,412 | $20 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 12 | $1,071 | $89 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 15 | $373 | $25 |
| Ultrasound of heart, follow-up | 15 | $315 | $21 |
| External ekg recording for more than 48 hours up to 21 days | 15 | $291 | $19 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 14 | $84 | $6 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 19 | $50 | $3 |
2017: 24 services
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 65 | $75,050 | $1,155 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 243 | $45,919 | $187 |
| Return visit (30+ min) | 235 | $29,435 | $83 |
| Injection, regadenoson, 0.1 mg | 112 | $19,351 | None |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 64 | $18,744 | $146 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 46 | $18,552 | $403 |
| New patient visit (45+ min) | 137 | $16,452 | $120 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 93 | $15,759 | $164 |
| Short return visit (20+ min) | 174 | $10,524 | $56 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 192 | $9,683 | $50 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 47 | $8,827 | $94 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 50 | $7,615 | $85 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 113 | $6,835 | $60 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 282 | $4,391 | $13 |
| Critical care, first 30-74 minutes | 13 | $4,134 | $180 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 49 | $3,633 | $59 |
| New patient visit (60+ min) | 16 | $2,410 | $151 |
| Electrocardiogram (ecg) 2-day continuous with review by health care professional | 54 | $1,189 | $22 |
| Electrocardiogram (ecg) 2-day continuous | 54 | $1,040 | $19 |
| Ultrasound of heart with probe in esophagus, with report | 11 | $986 | $90 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 82 | $634 | $7 |
| Ultrasound of heart, follow-up | 12 | $253 | $21 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 17 | $45 | $3 |
| Infusion, normal saline solution , 1000 cc | 24 | $36 | None |
2016: 20 services
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 37 | $42,925 | $1,160 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 223 | $42,569 | $188 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 53 | $21,643 | $408 |
| New patient visit (45+ min) | 165 | $21,245 | $129 |
| Short return visit (20+ min) | 219 | $15,447 | $58 |
| Injection, regadenoson, 0.1 mg | 88 | $14,618 | None |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 85 | $14,507 | $161 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 37 | $11,470 | $155 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 71 | $10,550 | $84 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 53 | $9,971 | $94 |
| Return visit (30+ min) | 82 | $7,763 | $82 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 113 | $5,833 | $51 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 93 | $5,383 | $58 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 191 | $2,610 | $14 |
| New patient visit (30+ min) | 25 | $2,076 | $83 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 164 | $1,184 | $7 |
| Electrocardiogram (ecg) 2-day continuous with review by health care professional | 46 | $1,022 | $22 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 14 | $935 | $58 |
| Electrocardiogram (ecg) 2-day continuous | 46 | $935 | $20 |
| Infusion, normal saline solution , 1000 cc | 37 | $56 | None |
2015: 12 services
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 51 | $10,087 | $190 |
| New patient visit (45+ min) | 54 | $7,180 | $133 |
| Return visit (30+ min) | 66 | $6,627 | $87 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 32 | $5,450 | $165 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 30 | $3,185 | $59 |
| Injection, regadenoson, 0.1 mg | 17 | $3,032 | None |
| Short return visit (20+ min) | 23 | $1,500 | $60 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 81 | $1,141 | $14 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 17 | $1,067 | $59 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 17 | $937 | $52 |
| Electrocardiogram (ecg) 2-day continuous with review by health care professional | 17 | $376 | $22 |
| Electrocardiogram (ecg) 2-day continuous | 17 | $338 | $20 |
Medicaid work
$2,217 in 2024
Medicaid paid $2,217 for 445 billed services this clinician did in 2024, up to 36 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 241 | $887 |
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 26 | $817 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 178 | $514 |
| 2024 | 445 | 3 | 36 | $2,217 |
| 2023 | 493 | 4 | 31 | $1,426 |
| 2022 | 64 | 3 | 14 | $325 |
| 2021 | 40 | 2 | 15 | $144 |
| 2020 | 13 | 1 | 13 | $9 |
| 2019 | 186 | 3 | 19 | $300 |
| 2018 | 445 | 5 | 29 | $6,871 |
See the largest Medicaid services in earlier years
2023
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 66 | $754 |
| Return visit (30+ min) | 222 | $371 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 192 | $288 |
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 13 | $12 |
2022
| Return visit (30+ min) | 26 | $248 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 26 | $78 |
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 12 | $0 |
2021
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 28 | $118 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 12 | $26 |
2020
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 13 | $9 |
2019
| Short return visit (20+ min) | 51 | $197 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 96 | $103 |
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 39 | $0 |
2018
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 94 | $2,379 |
| New patient visit (45+ min) | 49 | $1,885 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 201 | $1,504 |
| OFF/OP CNSLTJ NEW/EST MOD 40 | 15 | $977 |
| Short return visit (20+ min) | 86 | $126 |
Drugs they prescribed that Part D paid
$1,203,564
Pharmacies billed $1,203,564 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 7,833) in 2024. At or below the middle of the specialty; the typical cardiology clinician is at 0%.
6,759 generic and 1,074 brand-name prescriptions · $1,203,564 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Eliquis | 450 | $537,869 | $1,195 |
| Entresto | 144 | $211,735 | $1,470 |
| Xarelto | 110 | $138,916 | $1,263 |
| Repatha Sureclick | 132 | $115,427 | $874 |
| Jardiance | 20 | $32,080 | $1,604 |
See all 53 drugs
| Eliquis | 450 | $537,869 | $1,195 |
| Entresto | 144 | $211,735 | $1,470 |
| Xarelto | 110 | $138,916 | $1,263 |
| Repatha Sureclick | 132 | $115,427 | $874 |
| Jardiance | 20 | $32,080 | $1,604 |
| Farxiga | 12 | $18,193 | $1,516 |
| Metoprolol | 1,102 | $17,193 | $16 |
| Rosuvastatin | 500 | $7,783 | $16 |
| Praluent | 16 | $7,628 | $477 |
| Flecainide Acetate | 136 | $7,127 | $52 |
| Bumetanide | 94 | $6,754 | $72 |
| Amiodarone | 107 | $6,308 | $59 |
| Losartan | 633 | $6,014 | $10 |
| Potassium Chloride | 184 | $5,443 | $30 |
| Carvedilol | 542 | $4,920 | $9 |
| Atorvastatin | 474 | $4,791 | $10 |
| Amlodipine Besylate | 607 | $4,625 | $8 |
| Hydralazine | 255 | $4,450 | $17 |
| Diltiazem 24hr Er (La) | 39 | $4,393 | $113 |
| Icosapent Ethyl | 13 | $4,158 | $320 |
| Ezetimibe | 94 | $4,017 | $43 |
| Nitroglycerin | 306 | $3,170 | $10 |
| Nifedipine Er | 61 | $2,100 | $34 |
| Midodrine | 25 | $2,070 | $83 |
| Isosorbide Mononitrate Er | 153 | $1,931 | $13 |
| Lisinopril | 210 | $1,913 | $9 |
| Propafenone | 18 | $1,878 | $104 |
| Spironolactone | 190 | $1,845 | $10 |
| Clopidogrel | 121 | $1,824 | $15 |
| Furosemide | 197 | $1,114 | $6 |
| Olmesartan Medoxomil | 15 | $950 | $63 |
| Valsartan | 39 | $847 | $22 |
| Diltiazem | 28 | $807 | $29 |
| Chlorthalidone | 51 | $787 | $15 |
| Metoprolol | 101 | $762 | $8 |
| Diltiazem 24hr Er (Cd) | 36 | $731 | $20 |
| Doxazosin Mesylate | 34 | $634 | $19 |
| Cartia Xt | 18 | $614 | $34 |
| Klor-Con 10 | 18 | $524 | $29 |
| Benazepril | 32 | $440 | $14 |
| Propranolol | 15 | $439 | $29 |
| Irbesartan | 32 | $402 | $13 |
| Diltiazem 24hr Er | 13 | $377 | $29 |
| Hydrochlorothiazide | 63 | $371 | $6 |
| Losartan-Hydrochlorothiazide | 21 | $357 | $17 |
| Pravastatin | 22 | $353 | $16 |
| Lisinopril-Hydrochlorothiazide | 12 | $351 | $29 |
| Bisoprolol | 15 | $350 | $23 |
| Warfarin | 44 | $275 | $6 |
| Simvastatin | 23 | $206 | $9 |
| Clonidine | 15 | $192 | $13 |
| Atenolol | 41 | $147 | $4 |
| Amlodipine Besylate-Benazepril | 11 | $121 | $11 |
Year by year
| 2024 | 7,833 | 1,358 | 0% (0) | 14% | $1,203,564 |
| 2023 | 5,842 | 1,022 | 0% (0) | 14% | $770,980 |
| 2022 | 5,589 | 850 | 0% (0) | 12% | $585,078 |
| 2021 | 4,881 | 724 | 0% (0) | 13% | $458,336 |
| 2020 | 3,685 | 612 | None | 14% | $345,427 |
| 2019 | 3,227 | 483 | None | 14% | $242,716 |
| 2018 | 2,551 | 345 | None | 17% | $170,961 |
| 2017 | 1,321 | 203 | None | 29% | $95,851 |
| 2016 | 635 | 114 | None | 28% | $43,011 |
| 2015 | 117 | 38 | 0% (0) | 21% | $4,979 |
| 2014 | 197 | 48 | None | 12% | $9,010 |
| 2013 | 142 | 54 | None | 32% | $9,698 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 41 drugs
| Eliquis | 341 | $334,138 | $980 |
| Entresto | 106 | $144,019 | $1,359 |
| Xarelto | 85 | $103,898 | $1,222 |
| Repatha Sureclick | 37 | $39,802 | $1,076 |
| Metoprolol | 937 | $19,425 | $21 |
| Farxiga | 14 | $12,369 | $884 |
| Amiodarone | 99 | $9,289 | $94 |
| Rosuvastatin | 307 | $8,245 | $27 |
| Atorvastatin | 409 | $7,730 | $19 |
| Carvedilol | 445 | $6,439 | $14 |
| Potassium Chloride | 228 | $5,752 | $25 |
| Losartan | 376 | $5,150 | $14 |
| Flecainide Acetate | 88 | $5,147 | $58 |
| Bumetanide | 73 | $4,241 | $58 |
| Amlodipine Besylate | 364 | $3,905 | $11 |
| Nitroglycerin | 265 | $3,824 | $14 |
| Ezetimibe | 67 | $2,901 | $43 |
| Hydralazine | 147 | $2,682 | $18 |
| Lisinopril | 181 | $2,590 | $14 |
| Isosorbide Mononitrate Er | 127 | $2,347 | $18 |
| Midodrine | 31 | $2,307 | $74 |
| Diltiazem 24hr Er (La) | 17 | $2,199 | $129 |
| Furosemide | 220 | $1,644 | $7 |
| Spironolactone | 140 | $1,596 | $11 |
| Clopidogrel | 77 | $1,583 | $21 |
| Chlorthalidone | 39 | $1,322 | $34 |
| Diltiazem | 24 | $1,132 | $47 |
| Diltiazem 24hr Er (Cd) | 38 | $1,112 | $29 |
| Metoprolol | 99 | $1,104 | $11 |
| Nifedipine Er | 15 | $804 | $54 |
| Klor-Con 10 | 26 | $777 | $30 |
| Valsartan | 22 | $717 | $33 |
| Diltiazem 24hr Er (Xr) | 12 | $695 | $58 |
| Diltiazem 24hr Er | 20 | $525 | $26 |
| Irbesartan | 13 | $506 | $39 |
| Cartia Xt | 15 | $497 | $33 |
| Simvastatin | 14 | $364 | $26 |
| Hydrochlorothiazide | 53 | $307 | $6 |
| Doxazosin Mesylate | 13 | $300 | $23 |
| Atenolol | 35 | $286 | $8 |
| Warfarin | 21 | $231 | $11 |
2022: 42 drugs
| Eliquis | 311 | $246,956 | $794 |
| Entresto | 98 | $105,409 | $1,076 |
| Xarelto | 76 | $75,432 | $993 |
| Repatha Sureclick | 30 | $35,761 | $1,192 |
| Metoprolol | 1,050 | $19,867 | $19 |
| Amiodarone | 57 | $7,463 | $131 |
| Rosuvastatin | 228 | $6,851 | $30 |
| Atorvastatin | 436 | $6,185 | $14 |
| Pradaxa | 11 | $5,954 | $541 |
| Flecainide Acetate | 93 | $5,631 | $61 |
| Carvedilol | 373 | $4,694 | $13 |
| Nitroglycerin | 296 | $4,617 | $16 |
| Losartan | 344 | $3,906 | $11 |
| Potassium Chloride | 147 | $3,692 | $25 |
| Hydralazine | 172 | $3,137 | $18 |
| Bumetanide | 76 | $3,071 | $40 |
| Ezetimibe | 62 | $3,058 | $49 |
| Isosorbide Mononitrate Er | 175 | $2,431 | $14 |
| Diltiazem 24hr Er (Cd) | 53 | $2,128 | $40 |
| Amlodipine Besylate | 295 | $1,973 | $7 |
| Chlorthalidone | 53 | $1,749 | $33 |
| Lisinopril | 146 | $1,722 | $12 |
| Spironolactone | 156 | $1,681 | $11 |
| Clopidogrel | 91 | $1,190 | $13 |
| Furosemide | 156 | $1,002 | $6 |
| Diltiazem | 33 | $987 | $30 |
| Nifedipine Er | 16 | $758 | $47 |
| Valsartan | 20 | $697 | $35 |
| Diltiazem 24hr Er (Xr) | 20 | $574 | $29 |
| Diltiazem 24hr Er | 14 | $509 | $36 |
| Metoprolol | 52 | $501 | $10 |
| Cartia Xt | 14 | $446 | $32 |
| Klor-Con 10 | 17 | $443 | $26 |
| Simvastatin | 24 | $425 | $18 |
| Doxazosin Mesylate | 14 | $414 | $30 |
| Bisoprolol | 11 | $348 | $32 |
| Warfarin | 26 | $300 | $12 |
| Hydrochlorothiazide | 42 | $279 | $7 |
| Atenolol | 33 | $226 | $7 |
| Clonidine | 14 | $208 | $15 |
| Lisinopril-Hydrochlorothiazide | 13 | $125 | $10 |
| Alprazolam | 13 | $14 | $1 |
2021: 43 drugs
| Eliquis | 267 | $190,455 | $713 |
| Entresto | 83 | $75,438 | $909 |
| Xarelto | 36 | $43,343 | $1,204 |
| Metoprolol | 883 | $19,200 | $22 |
| Repatha Sureclick | 27 | $19,080 | $707 |
| Rosuvastatin | 256 | $9,605 | $38 |
| Amiodarone | 51 | $6,995 | $137 |
| Pradaxa | 13 | $6,323 | $486 |
| Atorvastatin | 387 | $6,186 | $16 |
| Nitroglycerin | 288 | $4,482 | $16 |
| Bystolic | 12 | $4,299 | $358 |
| Flecainide Acetate | 56 | $4,123 | $74 |
| Losartan | 282 | $3,970 | $14 |
| Bumetanide | 110 | $3,879 | $35 |
| Carvedilol | 364 | $3,724 | $10 |
| Cardizem La | 13 | $3,150 | $242 |
| Pacerone | 23 | $2,755 | $120 |
| Hydralazine | 192 | $2,735 | $14 |
| Diltiazem 24hr Er (Cd) | 65 | $2,599 | $40 |
| Potassium Chloride | 89 | $2,425 | $27 |
| Ezetimibe | 31 | $2,326 | $75 |
| Prasugrel | 11 | $2,026 | $184 |
| Spironolactone | 161 | $1,816 | $11 |
| Valsartan | 35 | $1,704 | $49 |
| Isosorbide Mononitrate Er | 122 | $1,695 | $14 |
| Amlodipine Besylate | 203 | $1,588 | $8 |
| Clopidogrel | 78 | $1,466 | $19 |
| Diltiazem 24hr Er | 28 | $1,069 | $38 |
| Midodrine | 16 | $1,068 | $67 |
| Chlorthalidone | 43 | $1,023 | $24 |
| Lisinopril | 122 | $969 | $8 |
| Cartia Xt | 17 | $863 | $51 |
| Furosemide | 114 | $650 | $6 |
| Metoprolol | 41 | $496 | $12 |
| Nifedipine Er | 18 | $476 | $26 |
| Warfarin | 32 | $469 | $15 |
| Atenolol | 25 | $404 | $16 |
| Diltiazem | 12 | $364 | $30 |
| Clonidine | 14 | $293 | $21 |
| Benazepril | 11 | $274 | $25 |
| Simvastatin | 17 | $208 | $12 |
| Hydrochlorothiazide | 31 | $183 | $6 |
| Lisinopril-Hydrochlorothiazide | 23 | $90 | $4 |
2020: 44 drugs
| Eliquis | 189 | $147,921 | $783 |
| Entresto | 58 | $48,960 | $844 |
| Xarelto | 38 | $41,837 | $1,101 |
| Metoprolol | 769 | $18,933 | $25 |
| Repatha Sureclick | 16 | $11,039 | $690 |
| Brilinta | 17 | $7,658 | $450 |
| Atorvastatin | 339 | $5,496 | $16 |
| Rosuvastatin | 96 | $4,637 | $48 |
| Nitroglycerin | 219 | $3,720 | $17 |
| Benicar Hct | 11 | $2,702 | $246 |
| Losartan | 190 | $2,533 | $13 |
| Bumetanide | 79 | $2,443 | $31 |
| Flecainide Acetate | 27 | $2,346 | $87 |
| Bystolic | 12 | $2,220 | $185 |
| Carvedilol | 204 | $1,989 | $10 |
| Prasugrel | 11 | $1,959 | $178 |
| Diltiazem 24hr Er (Cd) | 60 | $1,768 | $29 |
| Hydralazine | 80 | $1,640 | $20 |
| Diltiazem 24hr Er | 31 | $1,393 | $45 |
| Spironolactone | 133 | $1,341 | $10 |
| Midodrine | 23 | $1,219 | $53 |
| Ezetimibe | 23 | $1,146 | $50 |
| Valsartan | 18 | $1,076 | $60 |
| Amlodipine Besylate | 164 | $1,052 | $6 |
| Isosorbide Mononitrate Er | 68 | $1,005 | $15 |
| Clopidogrel | 46 | $915 | $20 |
| Potassium Chloride | 34 | $903 | $27 |
| Amiodarone | 35 | $889 | $25 |
| Lisinopril | 111 | $810 | $7 |
| Cartia Xt | 34 | $784 | $23 |
| Chlorthalidone | 23 | $731 | $32 |
| Irbesartan-Hydrochlorothiazide | 14 | $682 | $49 |
| Metoprolol | 79 | $620 | $8 |
| Furosemide | 82 | $582 | $7 |
| Dilt-Xr | 13 | $565 | $43 |
| Verapamil Er | 20 | $505 | $25 |
| Nifedipine Er | 11 | $502 | $46 |
| Warfarin | 36 | $443 | $12 |
| Hydrochlorothiazide | 28 | $212 | $8 |
| Clonidine | 11 | $201 | $18 |
| Pravastatin | 15 | $162 | $11 |
| Simvastatin | 16 | $146 | $9 |
| Lisinopril-Hydrochlorothiazide | 22 | $128 | $6 |
| Alprazolam | 15 | $20 | $1 |
2019: 32 drugs
| Eliquis | 163 | $110,235 | $676 |
| Xarelto | 41 | $30,288 | $739 |
| Entresto | 21 | $20,500 | $976 |
| Metoprolol | 624 | $18,143 | $29 |
| Atorvastatin | 306 | $5,077 | $17 |
| Amiodarone | 57 | $3,079 | $54 |
| Nitroglycerin | 162 | $2,654 | $16 |
| Bumetanide | 49 | $2,506 | $51 |
| Carvedilol | 192 | $2,072 | $11 |
| Rosuvastatin | 27 | $1,995 | $74 |
| Losartan | 124 | $1,560 | $13 |
| Spironolactone | 173 | $1,472 | $9 |
| Chlorthalidone | 46 | $1,422 | $31 |
| Diltiazem 24hr Er (Cd) | 45 | $1,306 | $29 |
| Lisinopril | 184 | $1,263 | $7 |
| Isosorbide Mononitrate Er | 100 | $1,111 | $11 |
| Amlodipine Besylate | 155 | $1,064 | $7 |
| Ezetimibe | 25 | $1,054 | $42 |
| Hydralazine | 53 | $927 | $17 |
| Valsartan | 11 | $798 | $73 |
| Cartia Xt | 34 | $739 | $22 |
| Diltiazem 24hr Er | 19 | $704 | $37 |
| Dilt-Xr | 22 | $592 | $27 |
| Furosemide | 104 | $575 | $6 |
| Diltiazem | 11 | $525 | $48 |
| Potassium Chloride | 21 | $501 | $24 |
| Metoprolol | 66 | $449 | $7 |
| Clopidogrel | 39 | $394 | $10 |
| Warfarin | 34 | $320 | $9 |
| Bisoprolol | 12 | $233 | $19 |
| Simvastatin | 17 | $135 | $8 |
| Hydrochlorothiazide | 27 | $117 | $4 |
2018: 32 drugs
| Eliquis | 127 | $75,615 | $595 |
| Xarelto | 25 | $21,232 | $849 |
| Metoprolol | 438 | $12,140 | $28 |
| Entresto | 19 | $9,827 | $517 |
| Atorvastatin | 255 | $3,512 | $14 |
| Nitroglycerin | 94 | $1,796 | $19 |
| Carvedilol | 201 | $1,464 | $7 |
| Spironolactone | 152 | $1,447 | $10 |
| Ezetimibe | 11 | $1,393 | $127 |
| Valsartan | 28 | $1,348 | $48 |
| Chlorthalidone | 48 | $1,258 | $26 |
| Isosorbide Mononitrate Er | 93 | $1,233 | $13 |
| Amiodarone | 50 | $1,027 | $21 |
| Lisinopril | 160 | $1,016 | $6 |
| Losartan | 92 | $764 | $8 |
| Diltiazem 24hr Er (Cd) | 38 | $754 | $20 |
| Cartia Xt | 28 | $688 | $25 |
| Diltiazem | 26 | $667 | $26 |
| Rosuvastatin | 24 | $651 | $27 |
| Dilt-Xr | 20 | $505 | $25 |
| Metoprolol | 67 | $473 | $7 |
| Furosemide | 108 | $455 | $4 |
| Amlodipine Besylate | 84 | $408 | $5 |
| Hydralazine | 32 | $405 | $13 |
| Enalapril Maleate | 12 | $372 | $31 |
| Nitroglycerin Patch | 14 | $338 | $24 |
| Clopidogrel | 43 | $333 | $8 |
| Warfarin | 22 | $211 | $10 |
| Potassium Chloride | 12 | $202 | $17 |
| Simvastatin | 18 | $168 | $9 |
| Klor-Con M20 | 13 | $159 | $12 |
| Hydrochlorothiazide | 18 | $71 | $4 |
2017: 23 drugs
| Eliquis | 123 | $57,598 | $468 |
| Xarelto | 16 | $8,228 | $514 |
| Metoprolol | 270 | $5,208 | $19 |
| Livalo | 12 | $2,973 | $248 |
| Atorvastatin | 141 | $1,696 | $12 |
| Nitroglycerin | 44 | $1,053 | $24 |
| Chlorthalidone | 29 | $927 | $32 |
| Rosuvastatin | 20 | $884 | $44 |
| Carvedilol | 78 | $551 | $7 |
| Spironolactone | 81 | $542 | $7 |
| Nitroglycerin Patch | 12 | $466 | $39 |
| Isosorbide Mononitrate Er | 43 | $463 | $11 |
| Lisinopril | 78 | $452 | $6 |
| Diltiazem 24hr Er | 23 | $434 | $19 |
| Enalapril Maleate | 12 | $425 | $35 |
| Clopidogrel | 33 | $306 | $9 |
| Cartia Xt | 22 | $291 | $13 |
| Losartan | 42 | $188 | $4 |
| Amlodipine Besylate | 49 | $173 | $4 |
| Simvastatin | 13 | $86 | $7 |
| Metoprolol | 17 | $82 | $5 |
| Clonidine | 15 | $71 | $5 |
| Furosemide | 23 | $45 | $2 |
2016: 15 drugs
| Eliquis | 63 | $24,790 | $393 |
| Metoprolol | 109 | $2,016 | $18 |
| Atorvastatin | 48 | $696 | $15 |
| Chlorthalidone | 24 | $684 | $29 |
| Nitroglycerin Patch | 11 | $378 | $34 |
| Diltiazem 24hr Er | 23 | $338 | $15 |
| Carvedilol | 39 | $249 | $6 |
| Amiodarone | 12 | $228 | $19 |
| Lisinopril | 39 | $192 | $5 |
| Spironolactone | 40 | $178 | $4 |
| Furosemide | 36 | $103 | $3 |
| Amlodipine Besylate | 29 | $82 | $3 |
| Losartan | 11 | $60 | $5 |
| Clopidogrel | 12 | $57 | $5 |
| Metoprolol | 15 | $44 | $3 |
2015: 3 drugs
| Atorvastatin | 11 | $119 | $11 |
| Metoprolol | 11 | $95 | $9 |
| Lisinopril | 14 | $60 | $4 |
2014: 8 drugs
| Metoprolol | 16 | $796 | $50 |
| Clopidogrel | 29 | $651 | $22 |
| Atorvastatin | 14 | $399 | $28 |
| Losartan | 13 | $229 | $18 |
| Isosorbide Mononitrate Er | 12 | $168 | $14 |
| Carvedilol | 20 | $161 | $8 |
| Metoprolol | 15 | $118 | $8 |
| Amlodipine Besylate | 11 | $77 | $7 |
2013: 4 drugs
| Atorvastatin | 15 | $517 | $34 |
| Metoprolol | 11 | $473 | $43 |
| Isosorbide Mononitrate Er | 12 | $260 | $22 |
| Metoprolol | 14 | $125 | $9 |
Money from drug and device companies
$32 in 2023
| 2023 | 1 | 2 | None | $32 |
| 2022 | 2 | 2 | None | $163 |
| 2021 | 1 | 1 | None | $129 |
| 2019 | 4 | 19 | None | $530 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Pfizer | Eliquis | $32 | 2 payments
|
See all 2 published payments
| Pfizer | Meals · 2023-11-13 | Eliquis | $18 |
| Pfizer | Meals · 2023-07-06 | Eliquis | $13 |
See earlier years (2022, 2021, 2019)
2022: $163
| Abbott Laboratories | Mitraclip | $143 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | Camzyos | $20 | 1 payment
|
2021: $129
| Abbott Laboratories | Mitraclip System | $129 | 1 payment
|
2019: $530
| Amgen | Repatha | $260 | 14 payments
|
| Abbott Laboratories | Heartmate 3 Left Ventricular Dev | $140 | 1 payment
|
| Medtronic Vascular | Arctic Front | $88 | 1 payment
|
| Novartis Pharmaceuticals | Entresto | $41 | 3 payments
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 85.8 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1720283393
- Licence
- CA 11348, TX BP1-0026266, TX N6161, WI 57394-21California G11348: CancelledTexas N6161: Canc Non-RenewalTexas BP10026266: Permit Terminated
- Group
- Community Foundation Medical Group · Fresno Community Hospital and Medical Center
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Cardiology (207RC0000X); Internal medicine (207R00000X)
- Mailing address
- 1313 E Herndon Ave Ste 203, Fresno, CA, 93720
- NPI first listed
- 2007-06-15
- NPI last updated
- 2015-08-10
This is when the NPI record was last certified, not a medical board exam.